CERTIS Therapeutics

What CERTIS Therapeutics does

CERTIS Therapeutics is a French privately-held medical device company (SAS, founded 27 September 2019, registered capital of €111,566) headquartered within the IHU Liryc institute in Pessac, Bordeaux, France. It is a spinoff from IHU Liryc, an international research center focused on cardiac electric disorders, and was founded to commercialize minimally invasive therapy solutions based on real-time MRI guidance.

The company's core offering is Certis Solution, a Software as a Medical Device (SaMD) that provides real-time 3D temperature mapping and motion-corrected thermometry during MRI-guided thermal ablation procedures, compatible with conventional 1.5T and 3T MRI scanners. The software stack comprises three proprietary modules — Certis Engine (thermometry computation), Certis Viewer (visualization, segmentation, registration, and streaming across the pre- to post-operative workflow), and Certis Transmitter (communication with MRI scanners, monitoring devices, and ablation devices). The technology is technique-agnostic across radiofrequency, microwave, laser, and focused ultrasound ablation, and is designed for multi-organ use (heart, liver, prostate, neurological). A second product, Horatio Prostate, is in development for prostate treatment applications.

CERTIS generates revenue through enterprise sales of its SaMD licenses and proprietary conformational ablation hardware to hospitals, academic centers, and cardiac electrophysiology and oncology/radiology departments. It relies on a direct field-sales go-to-market motion, distributing primarily through institutional relationships in France and broader Europe, with no disclosed customer logos, pricing, or sales volume. The company maintains a wide institutional partnership network (IHU Liryc, Université de Bordeaux, CHU de Bordeaux, CNRS, INSERM, French public funders) and was recognized in the 2019 I-LAB Innovation Competition.

Name

CERTIS Therapeutics

Legal name

Certis Therapeutics

Website

https://certis-therapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

CERTIS Therapeutics is a French medical device company that develops a Software as a Medical Device (Certis Solution) for real-time MRI-guided thermal ablation procedures, serving hospitals and cardiac, oncology, and radiology departments in Europe.

Ownership category

akta.pro rank

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)

Keywords

• MRI-guided ablation
• Thermal ablation software
• Interventional oncology
• Medical imaging software
• Cardiac electrophysiology

Headquarters

HQ city

Pessac

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Certis Solution Software: Certis Solution is a Software as a Medical Device (SaMD) providing real-time information during MRI-guided thermal ablation procedures. Revenue likely generated through software licensing, subscription, or perpetual license model to healthcare institutions.
2. Hardware Devices: The company develops proprietary ablation devices designed to achieve conformational accuracy, in addition to working with off-the-shelf ablation devices. Revenue may include hardware sales to medical institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

CERTIS Therapeutics develops and sells Certis Solution, a Software as a Medical Device (SaMD) that delivers real-time MRI thermometry and 3D temperature mapping with motion corrections during thermal ablation procedures. The company also designs proprietary conformal ablation hardware devices and offers Horatio Prostate for prostate treatment applications, serving hospitals and medical centers performing MRI-guided minimally invasive therapies.

Product overview

CERTIS Therapeutics offers a unified platform-plus-modules architecture centered on Certis Solution (a Software as a Medical Device) for MRI-guided thermal ablation procedures, supplemented by Horatio Prostate for specialized prostate applications. The company's technology combines real-time MRI guidance with software and hardware solutions for minimally invasive therapies, supporting multiple thermal ablation techniques including radiofrequency, microwaves, laser, and focused ultrasound.

Differentiator

Problem solved

Functional benefit

Brands

• Certis Solution: Software as a Medical Device (SaMD) providing real-time information during MRI-guided thermal ablation procedures, with modules for thermometry image computation, image visualization, and MRI communication.
• Horatio Prostate

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• IHU LiryccoreStrategic or Co-development PartnerIHU Liryc is the parent institute and leading international center focused on understanding and treating cardiac electric disorders. CERTIS Therapeutics is a spinoff from IHU Liryc, maintaining close institutional ties for research and development collaboration.
• Université de BordeauxcoreStrategic or Co-development PartnerMajor research university in Bordeaux, France. Contributes academic research capabilities and talent pipeline for the company's technology development.
• CHU de BordeauxcoreStrategic or Co-development PartnerCentre Hospitalier Universitaire de Bordeaux - main university hospital in the region. Provides clinical environment for testing and validating ablation technologies.
• Fondation Bordeaux UniversitéminorStrategic or Co-development PartnerUniversity foundation supporting research and innovation initiatives in the Bordeaux academic ecosystem.
• CNRScoreStrategic or Co-development PartnerCentre National de la Recherche Scientifique - France's largest fundamental research organization. Provides research expertise and scientific collaboration.
• INSERMcoreStrategic or Co-development PartnerInstitut National de la Santé et de la Recherche Médicale - French national institute for health and medical research. Provides biomedical research collaboration.
• UnitecminorStrategic or Co-development PartnerTechnology transfer and innovation support organization helping connect research with industry commercialization.
• PTIBminorStrategic or Co-development PartnerTechnology transfer and business incubator organization supporting innovative projects in the region.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• GE HealthCare: GE HealthCare manufactures MR scanners and has invested in MR-guided intervention suites and ablation/thermometry capabilities. As an installed-base incumbent, it is both a potential partner and a competitive threat to CERTIS's SaMD layer.
• AngioDynamics: AngioDynamics sells NanoKnife (irreversible electroporation) and other tumor ablation systems that are often integrated into image-guided workflows. It operates in the same oncology ablation segment CERTIS's Certis Solution is positioned to serve.
• Medtronic: Medtronic develops and markets a broad portfolio of ablation catheters and generators (RF, cryo, microwave) used by EP and oncology teams. It is a likely commercial partner for CERTIS's hardware devices and a powerful existing channel competing for the same ablation procedural budget.
• Philips Healthcare: Philips offers MR scanners, interventional guidance software, and an MR-guided therapy ecosystem that overlaps with CERTIS's thermal ablation SaMD offering. As a strategic imaging incumbent it could integrate CERTIS's capability or compete with a bundled solution.
• Siemens Healthineers: Siemens sells MR scanners (1.5T/3T) and integrates thermometry/real-time imaging sequences used to support MR-guided ablation workflows like CERTIS's. As the platform provider, Siemens controls the scanner-installed base on which CERTIS's software runs and could build or acquire competing capability.
• Boston Scientific: Boston Scientific is a major player in RF/microwave tumor ablation and cardiac EP ablation. Its installed ablation devices compete with CERTIS's planned conformal devices and represent a likely strategic acquirer or distribution partner.

Direct peers

• Monteris Medical: Monteris Medical offers NeuroBlate and AutoLITT, MR-guided laser interstitial thermal therapy systems for neurosurgery. The combination of proprietary ablation device with intra-procedural MR thermometry maps directly onto CERTIS's value proposition.
• Imricor Medical Systems: Imricor builds MR-compatible cardiac ablation catheters and related products for MR-guided electrophysiology. Both companies are addressing real-time MRI guidance for cardiac ablation and share the IHU-Liryc / cardiac EP clinical heritage.
• Insightec: Insightec commercializes Exablate, an MR-guided focused ultrasound platform for uterine fibroids, essential tremor, and other indications. It is the closest direct competitor in MR-guided focused ultrasound ablation and addresses the same clinical workflow problem CERTIS targets.
• Profound Medical: Profound Medical develops TULSA-PRO, an MRI-guided transurethral ultrasound ablation system for prostate tissue. Like CERTIS, it pairs an MR-compatible ablation modality with image-based real-time thermometry software, targeting the same image-guided therapy niche.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CERTIS Therapeutics